Ubiquigent Limited is continuing its collaboration with Bristol Myers Squibb. The collaboration, originally between Ubiquigent and Celgene, will allow Bristol Myers Squibb to capitalize on Ubiquigent’s deubiquitylase (DUB) enzyme inhibitor drug discovery platform and expertise.   The central role of ubiquitylation in diverse cellular processes, including protein degradation, makes the enzymes responsible for ubiquitylation and de-ubiquitylation very attractive drug targets to address a range of ...